Trial Profile

Phase Ib Study to Evaluate the Pharmacokinetics, Safety and Efficacy of TQB2450 Injection(PD-L1 Antibody) Combined With Anlotinib in Subjects With Advanced Cholangiocarcinoma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 09 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Benmelstobart (Primary) ; Catequentinib (Primary)
Indications Cholangiocarcinoma; Gallbladder cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Chia Tai Tianqing Pharmaceutical Group

Most Recent Events

01 May 2022 Results of pooled analysis from two phase Ib TQB2450-Ib-05 and TQB2450-Ib-08 trials published in the Hepatology
17 Jan 2021 Results (n=25) presented at the 2021 Gastrointestinal Cancers Symposium.
29 Oct 2019 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com